Everolimus (RAD001) + Everolimus Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberous Sclerosis Complex (TSC)
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Trial Timeline
Apr 1, 2009 → Nov 1, 2015
NCT ID
NCT00790400About Everolimus (RAD001) + Everolimus Placebo
Everolimus (RAD001) + Everolimus Placebo is a phase 3 stage product being developed by Novartis for Tuberous Sclerosis Complex (TSC). The current trial status is completed. This product is registered under clinical trial identifier NCT00790400. Target conditions include Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00790400 | Phase 3 | Completed |
Competing Products
13 competing products in Tuberous Sclerosis Complex (TSC)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Everolimus + Placebo | Novartis | Phase 3 | 77 |
| RAD001 | Novartis | Phase 1/2 | 41 |
| Placebo + Everolimus (RAD001) | Novartis | Phase 2 | 52 |
| RAD001 + Placebo | Novartis | Phase 2 | 52 |
| RAD001 + Placebo + Antiepileptic drug (1 to 3 only) + open label RAD001 (only used for post-extension phase) | Novartis | Phase 3 | 77 |
| Everolimus | Novartis | Phase 1/2 | 41 |
| everolimus (RAD001) | Novartis | Phase 1/2 | 41 |
| everolimus | Novartis | Phase 3 | 77 |
| sirolimus | Pfizer | Phase 2 | 51 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P | Jazz Pharmaceuticals | Phase 3 | 74 |
| GWP42003-P + Placebo | Jazz Pharmaceuticals | Phase 3 | 74 |
| Cannabidiol Oral Solution [Epidiolex] | Jazz Pharmaceuticals | Approved | 82 |